Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer. GSK announced on Monday that Omjjara, its brand name for momelotinib, has been granted marketing authorisation by the European Commission, giving the company permission to market the drug and make it available to patients and healthcare professionals across the EU and EEA-EFTA states of Iceland, Liechtenstein and Norway.

Omjjara is the first medicine in the continent specifically indicated for treating an enlarged spleen (known as splenomegaly) which is common with patients suffering from blood cancer myelofibrosis, specifically for those with moderate to severe anaemia.

GSK said that myelofibrosis affects an estimated one in 10,000 people in the EU, with nearly all patients likely to develop anaemia over the course of the disease.

"The challenges of living with myelofibrosis can be burdensome, and symptomatic patients can experience spleen enlargement, fatigue, night sweats and bone pain," said Nina Mojas, the senior vice president of GSK's Oncology Global Product Strategy unit.

"Until now, there have been no options specifically indicated to treat these symptoms in patients who also experience anaemia. The authorisation of Omjjara brings a new treatment option with a differentiated mechanism of action to these patients in the EU."

In a separate statement, GSK also said the the European Medicines Agency has accepted its Arexvy drug, developed for the prevention of respiratory syncytial virus (RSV) disease, for regulatory review.

The application follows positive results from a Phase III study showing immune response and an "acceptable tolerability profile" in adults aged 50-59 at increased risk. GSK said it is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.

Share this article

Related Sharecast Articles

Eli Lilly weight-loss drug 'significantly' reduces sleep apnoea
(Sharecast News) - Eli Lily's weight-loss drug tirzepatide has been shown to "significantly" reduce sleep apnoea severity, the US drugs giant said on Wednesday.
Royal Mail-owner rebuffs takeover approach
(Sharecast News) - Shares in International Distribution Services soared on Wednesday, after it emerged that Czech billionaire Daniel Kretinsky had made a takeover approach for the Royal Mail owner.
Just Eat shares drop as Q1 orders disappoint
(Sharecast News) - Shares in Just Eat dropped sharply on Wednesday after the food delivery marketplace delivered underwhelming order numbers for the first quarter, though revenue growth picked up sharply in the UK and Ireland.
Tekcapital's Innovative Eyewear inks deal with US firm
(Sharecast News) - Intellectual property investor Tekcapital announced a fresh development from its portfolio company Innovative Eyewear on Wednesday, as the latter launched a strategic partnership with Windsor Eyes, a prominent eyewear manufacturing and distribution firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.